The revised human liver cytochrome P450 "pie": Absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics

Drug Metabolism and Disposition

Volumn 42, Issue 8, 2014, Pages 1241-1251

  Michaels, Scott ^a,b   Wang, Michael Zhuo ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Wolfe Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4A; CYTOCHROME P450 4F2; FINGOLIMOD; LEUKOTRIENE B4; PAFURAMIDINE; PHYTOMENADIONE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; CYP3A PROTEIN, HUMAN; PROTEOME;

ADOLESCENT; ADULT; AEROBIC METABOLISM; AFRICAN AMERICAN; AGED; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HISPANIC; HUMAN; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUTRIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FAMILY; PROTEIN FOLDING; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; CHEMISTRY; ENZYMOLOGY; LIVER; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84904210746     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058040     Document Type: Article

References (39)

1. Araki N, Tsuruoka S, Hasegawa G, Yanagihara H, Omasa T, Enosawa S, Yamazoe Y, and Fujimura A (2012) Inhibition of CYP3A4 by 69,79- dihydroxybergamottin in human CYP3A4 overexpressed hepG2 cells. J Pharm Pharmacol 64:1715-1721.
2. Bardowell SA, Stec DE, and Parker RS (2010) Common variants of cytochrome P450 4F2 exhibit altered vitamin E-omega-hydroxylase specific activity. J Nutr 140:1901-1906.
3. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, and Eby C, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112.
4. Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, and Rettie AE, et al. (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166-38172.
5. Domanski TL, Finta C, Halpert JR, and Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392. (Pubitemid 32108573)
6. Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, and Rettie AE (2013) Cytochrome P450-dependent catabolism of vitamin K: v-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 52:8276-8285.
7. Fallon JK, Harbourt DE, Maleki SH, Kessler FK, Ritter JK, and Smith PC (2008) Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS. Drug Metab Lett 2:210-222.
8. Generaux CN, Ainslie GR, Bridges AS, Ismail MA, Boykin DW, Tidwell RR, Thakker DR, and Paine MF (2013) Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug. Drug Metab Dispos 41: 518-528.
9. Girault I, Rougier N, Chesné C, Lidereau R, Beaune P, Bieche I, and de Waziers I (2005) Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 33:1803-1810. (Pubitemid 41697265)
10. Guengerich FP(2005) Human cytochrome P450 enzymes, in: Cytochrome P450 Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed), pp 377-530, Kluwer Academic/Plenum, New York.
11. Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:2263-2275.
12. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304. (Pubitemid 34028540)
13. Hsu MH, Savas U, Griffin KJ, and Johnson EF (2007) Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39:515-538. (Pubitemid 47355735)
14. Jin R, Koop DR, Raucy JL, and Lasker JM (1998) Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Arch Biochem Biophys 359:89-98. (Pubitemid 28492435)
15. Jin Y, Zollinger M, Borell H, Zimmerlin A, and Patten CJ (2011) CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 39:191-198.
16. Ju W, Yang S, Ansede JH, Stephens CE, Bridges AS, Voyksner RD, Ismail MA, Boykin DW, Tidwell RR, and Hall JE, et al. (2014) CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement. J Pharm Sci 103:337-349.
17. Kalsotra A and Strobel HW (2006) Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther 112:589-611. (Pubitemid 44573491)
18. Kalsotra A, Turman CM, Kikuta Y, and Strobel HW (2004) Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol 199:295-304. (Pubitemid 39208729)
19. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel insilico peptide selection criteria. Pharm Res 25:1469-1483.
20. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, and Pearce RE (2005) Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 314:626-635. (Pubitemid 41043843)
21. Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, Ji C, Zhang B, Brayman TG, Lepsy C, and Heath TG, et al. (2008) Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 380:211-222.
22. McDonald MG, Rieder MJ, Nakano M, Hsia CK, and Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337-1346.
23. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162. (Pubitemid 35246494)
24. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
25. Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32:1146-1153. (Pubitemid 39287589)
26. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
27. Pastrakuljic A, Tang BK, Roberts EA, and Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53:531-538. (Pubitemid 27149546)
28. Powell PK, Wolf I, Jin R, and Lasker JM (1998) Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285:1327-1336. (Pubitemid 28277936)
29. Sehgal N, Agarwal V, Valli RK, Joshi SD, Antonovic L, Strobel HW, and Ravindranath V (2011) Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation. Biochem Pharmacol 82:53 - 64.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
31. Sontag TJ and Parker RS (2002) Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem 277:25290-25296. (Pubitemid 34951838)
32. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
33. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, and Erve JC, et al. (2004) Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112. (Pubitemid 38112542)
34. Wang MZ, Saulter JY, Usuki E, Cheung YL, Hall M, Bridges AS, Loewen G, Parkinson OT, Stephens CE, and Allen JL, et al. (2006) CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis (4-amidinophenyl)furan-bis-O- methylamidoxime]. 2,5-bis 4-amidinophenyl furan-bis-Omethylamidoxime Drug Metab Dispos 34:1985-1994. (Pubitemid 44837759)
35. Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, and Paine MF (2007) Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos 35:2067-2075. (Pubitemid 350005197)
36. Wang MZ, Wu JQ, Dennison JB, Bridges AS, Hall SD, Kornbluth S, Tidwell RR, Smith PC, Voyksner RD, and Paine MF, et al. (2008) A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 8:4186-4196.
37. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366. (Pubitemid 30137063)
38. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, and Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355. (Pubitemid 32924568)
39. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.